Nalkem Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 5.00 M
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 1013.29%
- Profit Growth -21.87%
- Ebitda -22.10%
- Net Worth -35.97%
- Total Assets -1.06%
About Nalkem Pharmaceuticals India
Nalkem Pharmaceuticals India Private Limited (NPIPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 November 2019 (Five years and two months 11 days old ). Its registered office is in Hyderabad, Telangana, India.
The Corporate was formerly known as Sridev Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Rajee Nalla, Venkata Lakkimsetty, Keerthi Katta, and One other member serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U33208TG2019PTC137114
-
Company No.
137114
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
25 Nov 2019
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Nalkem Pharmaceuticals India?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajee Nalla
|
Director | 16-Oct-2020 | Current |
|
Venkata Lakkimsetty
|
Additional Director | 17-Jun-2024 | Current |
|
Keerthi Katta
|
Director | 25-Nov-2019 | Current |
|
Jaya Nalla
|
Additional Director | 17-Jun-2024 | Current |
Financial Performance of Nalkem Pharmaceuticals India.
Nalkem Pharmaceuticals India Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 1013.29% increase. The company also saw a substantial fall in profitability, with a 21.87% decrease in profit. The company's net worth observed a substantial decline by a decrease of 35.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nalkem Pharmaceuticals India?
In 2022, Nalkem Pharmaceuticals India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Nalkem Pharma Private LimitedVenkata Lakkimsetty and Jaya Nalla are mutual person
-
Carmol Drugs Private Limited
Jaya Nalla is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nalkem Pharmaceuticals India?
Unlock and access historical data on people associated with Nalkem Pharmaceuticals India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nalkem Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nalkem Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
